CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 32 enrolled
Drug / intervention
Thalidomide +1 moredrug
Likely dose
Thalidomide 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00379353
NCT00379353Phase 2Completed
CompareCT.gov

The Effects of Thalidomide on Symptom Clusters

M.D. Anderson Cancer Center·interventional·Posted Sep 21, 2006·Updated Feb 4, 2013

In Brief

A Phase 2 clinical trial evaluating Thalidomide and Placebo for Advanced Cancers. Completed, enrolled 32 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if thalidomide can improve symptoms such as pain, fatigue,anxiety, poor appetite, depression, and sleep problems in patients with advanced cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancers
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 21, 2006
Enrollment StartSep 1, 2006
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 19.8 years ago

Interventions

Thalidomidedrug

100 mg capsules orally, once a day for 14 days.

Placebodrug

Two placebo capsules orally, once a day for 14 days.